The overall frequency of elevated hPGFS expression in SCCHN tumours (40.5%) exceeds the frequency of EGFR (32.4%), a well-known molecular marker and drug target for multiple types of tumours. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.